SMALLCAP PHARMA COMPANY SECURES LARGE MULTI-YEAR CDMO MANUFACTURING CONTRACT

has secured a multi-year Contract Development and Manufacturing Organization (CDMO) order valued at approximately Rs 825 crore from a leading global pharma major. The supplies under this order are expected to commence within the next 4–5 months, with execution scheduled through Q1 of the following financial year, subject to customary operational and regulatory processes. This order marks one of the most significant single CDMO mandates in the company’s history, as it scales its global manufacturing footprint. Having a market cap of Rs 2,421 crore, the company's stock price is trading at 2x of Book Value, making it a fair value for long term investing. Such new orders are expected to increase the company's revenue and profit growth.